hypertension Head of prevention and control of CVD disease office Ministry of heath

Similar documents
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Management of Hypertension

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

HTA. UMF Gatineau. Dr Tinouch Haghighat Cardiologue CSSSG-Hull

2003 World Health Organization (WHO) / International Society of Hypertension (ISH) Statement on Management of Hypertension.

Approach to patient with hypertension. Dr. Amitesh Aggarwal

5.2 Key priorities for implementation

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Management of Hypertension. Ahmed El Hawary MD Suez Canal University

New Hypertension Guideline Recommendations for Adults July 7, :45-9:30am

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Hypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH

What s New? Hypertension Canada Guidelines for the Management of Hypertension

2020 HYPERTENSION HIGHLIGHTS

How Low Do We Go? Update on Hypertension

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

RESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University

Management of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Egyptian Hypertension Guidelines

Jared Moore, MD, FACP

신장환자의혈압조절 나기영. Factors involved in the regulation of blood pressure

Difficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair

From the desk of the: THE VIRTUAL NEPHROLOGIST

Hypertension and Cardiovascular Disease

Summary of recommendations

Cardiac Pathophysiology

Diabetes and Hypertension

SAURIN GANDHI, AZCOM Evidence-Based Guideline for the Management of High Blood Pressure in Adults (JNC 8)

Combination Therapy for Hypertension

Hypertension. Most important public health problem in developed countries

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Hypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg

MPharmProgramme. Hypertension (HTN)

Hypertension Update Background

New Hypertension Guidelines. Kofi Osei, MD

CHALLENGES OF HYPERTENSION IN THE COALFACE

Adult Diabetes Clinician Guide NOVEMBER 2017

Hypertension Update. Aaron J. Friedberg, MD

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

Hypertension Clinical case scenarios for primary care

Incidental Findings; Management of patients presenting with high BP. Phil Swales

Hypertension Management - Summary

Clinical guideline Published: 24 August 2011 nice.org.uk/guidance/cg127

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Hypertension (JNC-8)

ANTI- HYPERTENSIVE AGENTS

Long-Term Care Updates

Disclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1

COMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC

Adult Blood Pressure Clinician Guide June 2018

HTN talk_l Davis_ /28/2018

What s In the New Hypertension Guidelines?

ESSENTIAL HYPERTENSION

Hypertension Management Controversies in the Elderly Patient

Management of High Blood Pressure in Adults

Long-Term Complications of Diabetes Mellitus Macrovascular Complication

IMET 2000 PAL International Medical Education Trust Palestine What the GP Should Know about Hypertension

DEPARTMENT OF GENERAL MEDICINE WELCOMES

The New Hypertension Guidelines

Antihypertensive Trial Design ALLHAT

2013 Hypertension Measure Group Patient Visit Form

ADVANCES IN MANAGEMENT OF HYPERTENSION

New indicators to be added to the NICE menu for the QOF and amendments to existing indicators

Hypertension Management Focus on new RAAS blocker. Disclosure

Dr Doris M. W Kinuthia

CONCORD INTERNAL MEDICINE HYPERTENSION PROTOCOL

Metabolic Syndrome and Chronic Kidney Disease

Update on Current Trends in Hypertension Management

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

Clinical Recommendations: Patients with Periodontitis

Genetic factors. A number of genetic factors or interactions between genes play a major role in essential hypertension.

CLINICAL GUIDELINE. Document No:CG38 *All Sites Management of adult patients referred to South Tees University Hospitals for hypertension.

The Failing Heart in Primary Care

Prevention of Heart Failure: What s New with Hypertension

ADVANCES IN MANAGEMENT OF HYPERTENSION

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Using the New Hypertension Guidelines

Metformin should be considered in all patients with type 2 diabetes unless contra-indicated

Hypertension Putting the Guidelines into Practice

major public health burden

Approach to Management of Hypertension. Prof. Abdulkareem Al-Suwaida, MD, FRCPC, MSc

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

How to Manage Resistant Hypertension Min Su Hyon, MD

Hypertension Putting the Guidelines into Practice

Blood Pressure Treatment in 2018

Systemic Hypertension Dr ahmed almutairi Assistant professor Internal medicine dept

INDIAN HYPERTENSION GUIDELINES-II

Heart Failure Clinician Guide JANUARY 2018

Hypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017


STANDARD treatment algorithm mmHg

Transcription:

hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath

RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT

Definition of hypertension Hypertension is sustained elevation of resting systolic BP ( 140mmhg),diastolic BP( 90mmhg),or both. Two type of hypertension was categorized: -Primary HTN,that hemodynamics and physiologic components vary indicating that primary HTN have no a single cause but multiple factors involved in sustaining elevated BP. -secondary HTN cause include renal parenchyma disease,renovascular diseas,pheochromacytoma,cushing, Hyper and hypothyroidism, alcohol consumption,coarctaion Of aorta, adrenal disease.

Key Messages for the Management of Hypertension 1. All adults should have their blood pressure assessed at all appropriate clinical visits. 2. Optimum management of the hypertensive patient requires assessment and communication of overall cardiovascular risk. 3. Home BP monitoring is an important tool in self-monitoring and self-management. 4. Treat to target. 5. Lifestyle modifications are effective in preventing hypertension, treating hypertension and reducing cardiovascular risk. 6. Combinations of both lifestyle changes and drugs are generally necessary to achieve target blood pressures. 7. Focus on adherence.

Reversible Risk Factors for Developing Hypertension Obesity Poor dietary habits High sodium intake Sedentary lifestyle High alcohol consumption

Prevalence of Hypertension 21.8% Number of adults + 15 suffering from hypertension 3.3% 21.8 % 52.4 % of those age 15 to 39 of those age 40 to 59 of those age 60 to 70 have hypertension.

Staging of hypertension for office blood pressure determination HYPERTENSION STAGE Normal Pre hypertension Stage1 hypertension SYSTOLIC PRESSURE)mmhg) <120 120-139 140-159 DIASTOLIC PRESSURE(mmhg( <80 80-89 90-99 Stage2 hypertension 160 100

Definition of HTN by office and out-of-office BP level category Systolic BP(mmhg) DdiastolicBP(m mhg) Office BP 140 and/or 90 Home BP 135 and/or 85 Amb BP Daytime(or awake) 135 and/or 85 Nighttime(or sleep( 120 and/or 70 24 hour 130 and/or 80

High Risk of Developing Hypertension in Those with pre hypertension pre hypertensive Individuals are at high risk of progression to overt hypertension. Annual follow-up of patients with pre - hypertension is recommended.

Blood Pressure Assessment: Patient preparation and posture 1.Standardized Preparation: 2.Patient 3.No acute anxiety, stress or pain. 4.No caffeine, smoking or nicotine in the preceding 30 minutes. 5.No use of substances containing adrenergic stimulants such as phenylephrine or pseudoephedrine (may be present in nasal decongestants or ophthalmic drops). 6.Bladder and bowel comfortable. 7.No tight clothing on arm or forearm. 8.Quiet room with comfortable temperature 9.Rest for at least 5 minutes before measurement 10.Patient should stay silent prior and during the procedure.

Blood Pressure Assessment: Patient preparation and posture Standardized technique: Posture The patient should be calmly seated with his or her back well supported and arm supported at the level of the heart. His or her feet should touch the floor and legs should not be crossed.

Blood Pressure Assessment: Patient position X

Criteria for the Diagnosis of Hypertension and Recommendations for Follow-up Elevated Out of the Office BP measurement Hypertension Visit 1 BP Measurement, History and Physical examination Elevated Random Office BP Measurement Hypertensive Urgency / Emergency Hypertension Visit 2 Target Organ Damage or Diabetes or BP >180/110? Yes Diagnosis of HTN No BP: 140-179 / 90-109 Clinic BPM ABPM (If available) Home BPM (If available)

Criteria for the Diagnosis of Hypertension and Recommendations for Follow-up Diagnosis of hypertension Non pharmacological treatment With or without pharmacological treatment *Consider home blood pressure measurement for follow-up readings, to assess for the presence of masked hypertension or white coat effect and to enhance adherence. Are BP readings below target during 2 consecutive visits? Follow-up at 3-6 month intervals * Yes No Symptoms, severe hypertension, intolerance to anti-hypertensive treatment or target organ damage Yes No More frequent visits * Visits every 1 to 2 months*

Criteria for the Diagnosis of Hypertension and Recommendations for Follow-up BP: 140-179 / 90-109 Clinic BPM ABPM (If available) Home BPM Hypertension visit 3 >160 SBP or >100 DBP <160 / 100 >140 SBP or >90 DBP < 140 / 90 or Hypertension visit 4-5 Diagnosis of HTN ABPM or HBPM Diagnosis of HTN Continue to follow-up Awake BP <135/85 and 24-hour <130/80 Continue to follow-up Awake BP >135 SBP or >85 DBP or 24-hour >130 SBP or >80 DBP Diagnosis of HTN < 135/85 Repeat Home BPM If < 135/85 Continue to follow-up >135 SBP or >85 DBP Diagnosis of HTN Patients with high normal blood pressure (office SBP 130-139 and/or DBP 85-89) should be followed annually. or

A assessment of the Overall Cardiovascular Risk Search for exogenous potentially modifiable factors that can induce/aggravate hypertension Prescription Drugs: NSAIDs, including coxibs Corticosteroids and anabolic steroids Oral contraceptive and sex hormones Vasoconstricting/sympathomimetic decongestants Calcineurin inhibitors (cyclosporin, tacrolimus) Erythropoietin and analogues Antidepressants: Monoamine oxidase inhibitors (MAOIs), SNRIs, SSRIs Midodrine Other: Licorice root Stimulants including cocaine Salt Excessive alcohol use

Assessment of the Overall Cardiovascular Risk Search for target organ damage Cerebrovascular disease 50% transient ischemic attack ischemic or hemorrhagic stroke vascular dementia Hypertensive retinopathy Left ventricular dysfunction Left ventricular hypertrophy 30% of hypertensive patients by Echo Coronary artery disease Ischemic heart disease more than 50% myocardial infarction congestive heart failure(the most common cause is HTN) Chronic kidney disease hypertensive nephropathy (GFR < 60 ml/min/1.73 m2) albuminuria Peripheral artery disease intermittent claudication ankle brachial index < 0.9

Assessment of the Overall Cardiovascular Risk Over 90% of hypertensive have other cardiovascular risks Assess and manage hypertensive patients for dyslipidemia, dysglycemia (e.g. impaired fasting glucose, diabetes) abdominal obesity, unhealthy eating and physical inactivity

Routine Laboratory Tests Preliminary Investigations of patients with hypertension 1. Urinalysis 2. Blood chemistry (potassium, sodium and creatinine) 3. Fasting glucose and/or glycated hemoglobin (A1c) 4. Fasting total cholesterol and high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), triglycerides 5. Standard 12-leads ECG Currently there is insufficient evidence to recommend routine testing of microalbuminuria in people with hypertension who do not have diabetes

Routine Laboratory Tests Follow-up investigations of patients with hypertension During the maintenance phase of hypertension management, tests (including electrolytes, creatinine, glucose, and fasting lipids) should be repeated with a frequency reflecting the clinical situation. Diabetes develops in 1-3%/year of those with drug treated hypertension. The risk is higher in those treated with a diuretic or beta blocker, in the obese, sedentary, with higher fasting glucose and who have unhealthy eating patterns. Assess for diabetes more frequently in these patients.

The Role of Echocardiography Echocardiography is useful for: Assessment of left ventricular dysfunction and the presence of left ventricular hypertrophy Echocardiography is not useful for routine evaluation of hypertensive patients

The Role of Echocardiography Echocardiography is useful for: Assessment of left ventricular dysfunction and the presence of left ventricular hypertrophy Echocardiography is not useful for routine evaluation of hypertensive patients

Treatment Algorithm for Isolated Systolic Hypertension without Other Compelling Indications TARGET <140 mmhg (< 150 mmhg if age > 60 years) INITIAL TREATMENT AND MONOTHERAPY Lifestyle modification therapy Thiazide diuretic ARB Long-acting DHP CCB

Add-on Therapy for Systolic/Diastolic Hypertension without Other Compelling Indications If partial response to monotherapy 1. Add-on Therapy 2. Triple or Quadruple Therapy IF BLOOD PRESSURE IS NOT CONTROLLED CONSIDER No adherence Secondary HTN Interfering drugs or lifestyle White coat effect If blood pressure is still not controlled, or there are adverse effects, other classes of antihypertensive drugs may be combined (such as alpha blockers or centrally acting agents).

Drug Combinations When combining drugs, use first-line therapies. Two drug combinations of beta blockers, ACE inhibitors and angiotensin receptor blockers have not been proven to have additive hypotensive effects. Therefore these potential two drug combinations should not be used unless there is a compelling (non blood pressure lowering) indication Combinations of an ACEI with an ARB do not reduce cardiovascular events more than the ACEI alone and have more adverse effects therefore are not generally recommended

Drug Combinations Caution should be exercised in combining a non dihydropyridine CCB and a beta blocker to reduce the risk of bradycardia or heart block. Monitor serum creatinine and potassium when combining K sparing diuretics (such as aldosterone antagonists), ACE inhibitors and/or angiotensin receptor blockers. If a diuretic is not used as first or second line therapy, triple therapy should include a diuretic, when not contraindicated.

Choice of Pharmacological Treatment for Hypertension Individualized treatment Compelling indications: Ischemic Heart Disease Recent ST Segment Elevation-MI or non-st Segment Elevation-MI Left Ventricular Systolic Dysfunction Cerebrovascular Disease nicardipine labetolol.nitroproside Left Ventricular Hypertrophy Non Diabetic Chronic Kidney Disease Renovascular Disease Smoking Diabetes Mellitus With Nephropathy ARB but NO amlodipine Without Nephropathy Global Vascular Protection for Hypertensive Patients Statins if 3 or more additional cardiovascular risks Aspirin once blood pressure is controlled

Vascular Protection for Hypertensive Patients: Statins In addition to current recommendations on management of dyslipidemia, statins are recommended in high-risk hypertensive patients with established atherosclerotic disease or with at least 3 of the following criteria: Male Age 55 or older Smoking Total-C/HDL-C ratio of 6 mmol/l or higher Family History of Premature CV disease LVH ECG abnormalities Microalbuminuria or Proteinuria

Summary: Treatment of Isolated Systolic Hypertension without Other Compelling Indications TARGET <140 mmhg, < 150 mmhg for age > 60years Lifestyle modification therapy Thiazide diuretic ARB Long-acting DHP CCB CONSIDER Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect Dual therapy Triple therapy *If blood pressure is still not controlled, or there are adverse effects, other classes of antihypertensive drugs may be combined (such as ACE inhibitors, alpha blockers, centrally acting agents, or nondihydropyridine calcium channel blocker).

Summary: Treatment of Systolic-Diastolic Hypertension without Other Compelling Indications TARGET <140/90 mmhg Lifestyle modification Initial therapy A combination of 2 first line drugs may be considered as initial therapy if the blood pressure is >20 mmhg systolic or >10 mmhg diastolic above target Thiazide diuretic ACEI ARB Long-acting CCB Betablocker* CONSIDER Nonadherence Secondary HTN Interfering drugs or lifestyle White coat effect Dual Combination Triple or Quadruple Therapy *Not indicated as first line therapy over 60 y